PharVision Advisers’s Scotiabank BNS Stock Holding History

PharVision Advisers’s Portfolio BNS Stock Details BNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,241	Closed	-$210K	–	717
2025 Q3	$210K	Buy	+3,241	New	+$191K	0.12%	481

Other funds holding BNS

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

PharVision Advisers's BNS Position: Q4 2025 in Review

PharVision Advisers sold out of Scotiabank (BNS) in Q4 2025, closing a stake of 3,241 shares — an estimated $210K sold.

PharVision Advisers first reported a position in BNS in Q3 2025 and held it in 1 quarter. The position peaked at $210K in Q3 2025. 483 funds tracked by Wall St. Rank hold BNS as of Q4 2025.

PharVision Advisers reported no remaining Scotiabank position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 3,241 Scotiabank shares in Q4 2025, an estimated $210K.
PharVision Advisers first reported a position in Scotiabank in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Scotiabank position peaked at $210K in Q3 2025.
483 funds tracked by Wall St. Rank held Scotiabank as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.